Champions Oncology (CSBR) Fundamental Analysis: Revenue, Earnings & Valuation

6.26 / 10

Outperform

CSBR's fundamental profile is constructive, earning a 6.3/10 rating. Key strengths include an Inventory turnover ratio of 126.8281 and an Interest coverage ratio (EBIT / Interest expense) of 48.5879, both indicating efficient operations and solid interest payment capacity. However, the PB-ROE factor of 1.9060 places it in the lowest-performing group, suggesting potential overvaluation relative to peers. Overall, the company demonstrates adequate financial health with room for improvement in valuation metrics.

Analysis Checks(9/10)

Revenue-MV

Value-0.43

Score3/3

Weight24.03%

1M Return11.03%

Total operating revenue (YoY growth rate %)

Value13.54

Score3/3

Weight1.55%

1M Return0.88%

Inventory turnover ratio

Value126.83

Score2/3

Weight-2.00%

1M Return-1.23%

Profit-MV

Value-2.41

Score3/3

Weight23.99%

1M Return10.40%

PB-ROE

Value1.91

Score0/3

Weight6.87%

1M Return3.36%

Interest coverage ratio (EBIT / Interest expense) (%)

Value48.59

Score2/3

Weight-2.08%

1M Return-1.25%

Operating revenue (YoY growth rate %)

Value13.54

Score2/3

Weight0.18%

1M Return0.10%

Asset-MV

Value-1.91

Score3/3

Weight30.60%

1M Return11.94%

Net profit / Total profit (%)

Value101.62

Score2/3

Weight-1.64%

1M Return-0.98%

Cash-MV

Value0.40

Score2/3

Weight18.51%

1M Return8.80%

Is CSBR undervalued or overvalued?

CSBR scores 6.26/10 on fundamentals and holds a Discounted valuation at present. Backed by its -4.22% ROE, 4.16% net margin, 36.51 P/E ratio, 21.50 P/B ratio, and 460.00% earnings growth, these metrics solidify its Outperform investment rating.